Restless Legs Syndrome

William G. Ondo

doi:10.1016/j.ncl.2009.04.007

Restless Legs Syndrome

William G. Ondo

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Restless legs syndrome (RLS) affects many people. General population prevalence surveys usually range from 1% to 12%, but most European ancestry studies suggest 10%. The development of validated rating scales and standardized diagnostic criteria have vastly improved the quality of RLS treatment trials. Although multiple medications have shown outstanding efficacy, all of them are felt to provide only symptomatic relief, rather than any "curative" effect. Dopamine agonists are clearly the best investigated and probably the most effective treatments for RLS.

Original language	English (US)
Pages (from-to)	779-799
Number of pages	21
Journal	Neurologic Clinics
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.ncl.2009.04.007
State	Published - Aug 2009

Keywords

Dopamine
Genetics
Iron
Restless legs syndrome
Treatment

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/j.ncl.2009.04.007

Cite this

@article{fa845f7d59b84d669478150cb431bf37,

title = "Restless Legs Syndrome",

abstract = "Restless legs syndrome (RLS) affects many people. General population prevalence surveys usually range from 1% to 12%, but most European ancestry studies suggest 10%. The development of validated rating scales and standardized diagnostic criteria have vastly improved the quality of RLS treatment trials. Although multiple medications have shown outstanding efficacy, all of them are felt to provide only symptomatic relief, rather than any {"}curative{"} effect. Dopamine agonists are clearly the best investigated and probably the most effective treatments for RLS.",

keywords = "Dopamine, Genetics, Iron, Restless legs syndrome, Treatment",

author = "Ondo, {William G.}",

year = "2009",

month = aug,

doi = "10.1016/j.ncl.2009.04.007",

language = "English (US)",

volume = "27",

pages = "779--799",

journal = "Neurologic Clinics",

issn = "0733-8619",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Restless Legs Syndrome

AU - Ondo, William G.

PY - 2009/8

Y1 - 2009/8

N2 - Restless legs syndrome (RLS) affects many people. General population prevalence surveys usually range from 1% to 12%, but most European ancestry studies suggest 10%. The development of validated rating scales and standardized diagnostic criteria have vastly improved the quality of RLS treatment trials. Although multiple medications have shown outstanding efficacy, all of them are felt to provide only symptomatic relief, rather than any "curative" effect. Dopamine agonists are clearly the best investigated and probably the most effective treatments for RLS.

AB - Restless legs syndrome (RLS) affects many people. General population prevalence surveys usually range from 1% to 12%, but most European ancestry studies suggest 10%. The development of validated rating scales and standardized diagnostic criteria have vastly improved the quality of RLS treatment trials. Although multiple medications have shown outstanding efficacy, all of them are felt to provide only symptomatic relief, rather than any "curative" effect. Dopamine agonists are clearly the best investigated and probably the most effective treatments for RLS.

KW - Dopamine

KW - Genetics

KW - Iron

KW - Restless legs syndrome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=67449098375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449098375&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2009.04.007

DO - 10.1016/j.ncl.2009.04.007

M3 - Review article

C2 - 19555831

AN - SCOPUS:67449098375

SN - 0733-8619

VL - 27

SP - 779

EP - 799

JO - Neurologic Clinics

JF - Neurologic Clinics

IS - 3

ER -

Restless Legs Syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this